创新药板块“过热”？绩优基金限购背后的投资逻辑

Group 1 - The core viewpoint of the news is that several funds focused on innovative pharmaceuticals have implemented subscription restrictions to ensure stable operations and protect the interests of existing investors [1][2][3][4] - The China Europe Medical Innovation Fund suspended large subscriptions starting August 11, with a limit of 100,000 yuan per account per day [2] - Other funds, such as Huatai-PineBridge Hong Kong Advantage Select and Yongying Ruixin Mixed Fund, also announced similar restrictions, indicating a trend among high-performing funds in the innovative drug sector [3][4] Group 2 - The innovative drug sector has seen significant growth this year, with the National Index for Hong Kong Stock Connect Innovative Drugs rising over 102% year-to-date as of August 8 [4] - The performance of these funds has attracted substantial capital inflow, leading to concerns about whether the innovative drug market is overheating [4][5] - Analysts suggest that the subscription limits are primarily to control fund size, protect investor interests, and match the liquidity of underlying assets [5]